Background. Ventral incisional hernia is the most common long-term complication after an abdominal operation. Among newly diagnosed colorectal cancer patients, we screened the preoperative plasma proteome to explore predictive markers for the development of an incisional hernia. Methods. We utilized preoperative plasma samples of 72 newly diagnosed colorectal cancer patients who underwent midline incision for tumor resection between 2010 and 2013. A total of 21 patients with incisional hernia occurrence were matched with 51 patients with at least 18 months follow-up without an incisional hernia by sex, age, and body mass index. To assess predictive markers of incisional hernia risk, we screened the plasma proteome for >2,000 distinct proteins using a well-validated antibody microarray test. Paired t tests were used to compare protein levels between cases and controls. A gene-setenrichment analysis (Gene Ontology and Kyoto Encyclopedia of Genes and Genomes) was applied to test for differences in signaling pathways between the 2 groups.
VENTRAL INCISIONAL HERNIA is the most common long-term complication after laparotomy and is a continuing problem for the abdominal surgeon. By definition, hernias develop due to a defect in an aponeurotic tissue layer (eg, at the incisional site after an abdominal operation), leading to the protrusion of an organ out of its natural cavity. 1 Incisional hernias occur more frequently after midline incisions compared with a transverse incisional approach. 2 Incisional hernia incidence after elective midline incision (eg, for the oncologic resection of colorectal cancer) is high at a reported 10-40%. 3, 4 Most incisional hernias develop within 2 years after an operation 5 and can cause severe health and cosmetic problems. Each year, over 340,000 hernia repairs are performed in the United States, causing health care costs of at least $3.2 billion. 6 These figures illustrate the tremendous economic burden associated with the incidence and repair of incisional hernia and, consequently, demonstrate the importance of a multidirectional approach in the prevention of this complication.
Preventive measures are available, such as prophylactic mesh implantation, leading to a reduction of an incisional hernia within 2 years after an operation. 7 After analysis of the existing evidence, however, the European Hernia Society concluded: "Although the data are favorable and consistent for prophylactic mesh augmentation, the Guidelines Development Group decided that larger trials are needed to make a strong recommendation to perform prophylactic mesh augmentation for all patients within certain risk groups." 8 Not all patients experience the same risk of developing an incisional hernia, and the pathogenic mechanism of incisional hernia development is not fully understood. The genesis of an incisional hernia is multifactorial: generally, conditions that negatively affect wound healing make patients susceptible to incisional hernia. Contributing factors may be divided into patient-and surgeon-related factors, which are to some extent directly controllable. 1, [9] [10] [11] [12] [13] [14] [15] Surgery-related factors include suture material, poor technique, and the need for emergency surgery. 16 Furthermore, postoperative wound infection at the operative site has been identified as a major contributing factor, with up to 25% of patients developing an incisional hernia. 17, 18 Patient-related factors that contribute to the development of incisional hernia include, among others, age, obesity, smoking, malnutrition, immunosuppressive therapy, and connective tissue disorders. 19 Moreover, a positive family history of incisional hernia contributes to an elevated risk. 20 These findings support the hypothesis that certain individual biologic factors may significantly increase the risk for incisional hernia development. Alterations in connective tissue metabolism, such as changes in the extracellular matrix, have been reported, including thinner collagen fibrils, imbalance between type I and type III collagen, and increased activity of collagen degrading matrix metalloproteinases (MMPs). 21, 22 A decreased ratio of type I to III collagen and MMP-1/MMP-2 ratios in fascia tissue 23 and a systemic alteration of collagen metabolism 24 have been reported in hernia patients, which might explain biologic activities of key elements in the development of incisional hernia.
A predictive tool to precisely identify patients that are at high risk for an incisional hernia is an unmet clinical need. A validated risk model shows predictive value for abdominal wound dehiscence, 16 and a predictive model for estimating the risk of early incisional hernia has been developed 25 ; however, no preoperative biomarker that predicts incisional hernia development prior to a planned operation currently exists. Such a biomarker, alone or incorporated into a multifactorial model, could guide decision-making for early preventive measures (eg, mesh implantation at primary operation) and personalized recommendations for patients at risk.
Thus, we tested an array-based strategy for the discovery of predictive biomarker candidates among newly diagnosed colorectal cancer patients undergoing median laparotomy using preoperative plasma samples while accounting for known clinical risk factors.
PATIENTS AND METHODS
Patients. This pilot, case-control study is nested in the Heidelberg, Germany, site of the ColoCare Consortium. ColoCare is an international, multicenter, prospective cohort, with additional US sites at the Fred Hutchinson Cancer Research Center, Seattle, WA; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; and Huntsman Cancer Institute, Salt Lake City, UT, recruiting newly diagnosed colorectal cancer patients (International Classification of Diseases, 10th edition, C18-C20) of all stages with the goal to investigate predictors of cancer recurrence, survival, treatment toxicities, and health-related quality of life (ClinicalTrials.gov: NCT02328677).
All ColoCare patients included in this study underwent clinically indicated midline incision along the linea alba for colorectal cancer removal at a single institution (Department of General, Visceral, and Transplantation Surgery, University Hospital of Heidelberg) between October 2010 and January 2013.
Out of 265 patients enrolled in ColoCare, 72 who met the following inclusion criteria were included in the study: midline incision, preoperative blood, no mesh implantation at the primary operation, no burst abdomen in the control group, complete clinical data on risk factors, follow-up >18 months, and a phone interview to confirm presence or absence of incisional hernia. A study flow diagram is presented in the Figure. Characteristics of the 193 patients excluded from the study were similar to the patients included in the study, except that the included patients were an average of 5 years younger (see Supplementary Table I ). Of the 72 included patients, 21 had developed an incisional hernia (cases) and were matched to the 51 patients without hernia (controls).
A step-wise matching procedure was performed. In a first matching step, we included all variables of interest: sex, age, body mass index (BMI), smoking, adjuvant chemotherapy, impaired wound healing, and diabetes. In the proceeding matching steps, variables were dropped consecutively. Patients were matched by at least sex, age, and BMI. Table I shows patient characteristics abstracted from patients' medical records.
The study was approved by the Institutional Review Board of the Medical Faculty at the University of Heidelberg, and all participants provided written informed consent.
Definition of incisional hernia cases and controls. The incidence of an incisional hernia at the midline incision site was assessed by a dual assessment of questionnaires and phone interviews. As a first step, we queried all patients for incisional hernia occurrences (along with a lay explanation and graphical illustration) via questionnaires at 6, 12, and 24 months postoperation (see Supplementary Table II) . Second, we performed a comprehensive phone interview with the patient to verify whether an incisional hernia had occurred (see Supplementary Table III) . If a patient was not available by phone or the presence of incisional hernia remained unclear, the interview was conducted with the corresponding general practitioner.
All incisional hernia cases reported the confirmation of hernia as part of a study-unrelated physical examination (eg, with their general practitioner) or an operative hernia repair. In addition, some cases reported confirmation by sonography (n = 6) and internal computed tomography scans were evaluated that confirmed hernia formation in 3 cases. Patients were defined as controls if no incisional hernia had occurred within at least 18 months postoperation, which was the time of the latest case of incisional hernia reported in the case group.
Plasma processing. Blood samples (EDTA) were collected from patients prior to operation. [29] [30] [31] Briefly, antibodies were printed in triplicates on Nexterion H hydrogel slides (Schott, Mainz, Germany) in 48 blocks with a 15 3 15 block format for a total of 3,600 unique features at a final concentration of 275 mg/mL. After depletion of albumin and IgG, the remaining plasma proteins (200 mg) were labeled with Cy5 (cases and controls) or Cy3 (reference) (GE Health Biosciences, Pittsburgh, PA) after a "case/control versus reference" procedure to remove dye bias from the analysis. After plasma was incubated on arrays, arrays were washed and scanned using an Axon GenePix 4200A microarray scanner (Molecular Devices, Sunnyvale, CA). GenePix Pro 6.0 (Molecular Devices, Sunnyvale, CA) image analysis software was used to analyze the scanned array images.
Statistical analysis. Detailed descriptions of array statistical analysis have been reported previously. 32 Briefly, for each antibody feature, the fold change of case and control signal (red channel) relative to the reference (green channel) was calculated as log 2 (R c /G c ), where R c is red corrected and G c is green corrected applying a normexp background correction method. 33 Paired t test was performed to assess the difference between case and control signal for each antibody. The P values calculated via the paired t test represent the ability of the protein marker to distinguish cases from controls. Protein markers were then ranked based on the coefficient, also known as the odds ratio, which is a log 2 -based measurement of signal intensity and represents a 2-fold change. Markers with positive coefficients are greater in cases versus controls, and negative coefficients represent the converse.
Gene set enrichment analysis was performed based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) and gene ontology (GO) gene sets that are available from the Molecular Signatures Database (http://www.broadinstitute.org/ gsea/msigdb/index.jsp). The 889 antibodies available for analysis correspond to 732 unique genes. Of the 990 GO gene sets analyzed, our array included $5 gene members in 835 of these gene sets. With respect to KEGG gene sets, our arrays included $5 proteins corresponding to gene members in 129 of the 131 gene sets available. We then tested whether the proteins corresponding to groups of genes in a given gene set had a higher statistical ranking than the proteins not in this gene set based on Wilcoxon testing. R statistical computing software program was used for all statistical array analyses incorporating the "limma" package for microarray read in and normalization. 34 Matching of cases and controls and the analyses of the study population's characteristics were performed using SAS software (SAS 9.3; SAS Institute, Cary, NC). Comparison of quantitative variables was performed by parametric Student t tests. Pearson v 2 tests were used to investigate differences between categorical variables.
RESULTS
The case and control groups were balanced with respect to age, sex, BMI, tumor location, and stage. Somewhat greater proportions of postoperative wound disorder, diabetes, and a history of other type of hernia (eg, inguinal hernia) were found in the incisional hernia case group. Most incisional hernias (65%) occurred within the first 12 months postoperation. The study population's demographic and clinical characteristics are shown in Table I .
Of the 3,290 proteins assessed in the paired t test, 25 (0.8%) showed statistically significant differences in signal between cases and controls at P < .05 with a reasonable effect size and log 2 ratio of >1 or <À1. Of these 25 proteins, 12 were lower and 13 higher in cases compared to controls (Table II) . The top half of proteins that were lower in cases than in controls included proteasome subunit beta type 5 (À1.52 log 2 ratio), sex hormonebinding protein (À1.49 log 2 ratio), defensin alpha 1 (À1.34 log 2 ratio), chemokine (C-C motif) ligand 21 (À1.3 log 2 ratio), SRA (steroid receptor RNA activator) stem-loop interacting RNA binding protein (À1.22 log 2 ratio), and epithelial cell adhesion molecule (À1.13 log 2 ratio). The top half of proteins that were higher in cases than in controls included RNA polymerase III transcription initiation factor (1.78 log 2 ratio), calreticulin 3 (1.36 log 2 ratio), estrogen receptor 1 (1.32 log 2 ratio), Harvey rat sarcoma viral oncogene homolog (1.2 log 2 ratio), and fibronectin 1 (1.18 log 2 ratio). A lower effect size of >0.5 or <-0.5 with P values < .05 revealed an additional 62 proteins that were different between cases and controls (Table III) , including collagen type I alpha 1 (0.82 log 2 ratio), interleukin 1 beta (0.78 log 2 ratio), fibrillin 2 (0.77 log 2 ratio), granulin (À0.51 log 2 ratio), nidogen 1 (-0.63 log 2 ratio), and collagen type XXIV alpha 1 (-0.90 log 2 ratio).
In our gene set analysis, a total of 11 KEGG and 123 GO gene sets had a P value < .05 (Table IV) . These pathways include extracellular matrix receptor interaction (P = .0002), intestinal immune network for IgA production (P = .0024), progesterone mediated oocyte maturation (P = .0062), melanoma (P = .0073), bladder cancer (P = .0084), complement and coagulation cascades (P = .0112), ubiquitin mediated proteolysis (P = .0175), focal adhesion (P = .0224), regulation of actin cytoskeleton (P = .0267), pathways in cancer (P = .0272), and toll-like receptor signaling pathway (P = .0005) (Table IV) .
Results were consistent when removing 9 patients (n = 4 cases; n = 5 controls) with a previous inguinal or umbilical hernia from the analysis.
DISCUSSION
Given the tremendous economic and patient burden, precision prevention of incisional hernias is an unmet clinical need. A precise risk prediction would allow personalized operative measures in high-risk patients (eg, preventive mesh implantation during the primary operation) and individual patient recommendations to prevent the development of an incisional hernia. Certain risk factors have been identified. To date, however, no predictive preoperation blood-based biomarker is available to evaluate a patient's individual risk for an incisional hernia. In preoperative plasma of colorectal cancer patients, we identified 25 proteins that were either nominally significantly elevated (13) or reduced (12) with a reasonable effect size (log 2 ratio >1 or <À1) in future incisional hernia patients. Most of these proteins are connected to cell adhesion, wound healing, and inflammation. The cell adhesion molecules protocadherin-15, P-cadherin, and epithelial cell adhesion molecule were decreased in future incisional hernia patients and have previously been associated with wound healing and tissue integrity. [35] [36] [37] Furthermore, we observed decreased plasma levels of CC-chemokine ligand 21, a chemokine involved in inflammatory processes, in hernia cases compared to controls. Intradermal injection of CCchemokine ligand 21 has been shown to increase the migration of mesenchymal stem cells resulting in accelerated wound repair in mice. 38 Moreover, sex hormone-binding globulin (SHBG) was decreased in future incisional hernia cases by a log 2 ratio of -1.49 compared to controls, while estrogen receptor 1 was increased (log 2 ratio of 1.32). Topical estrogen application has been shown to support wound healing in a randomized controlled trial, 39 and elevated estrogen receptor 1 plasma levels may reflect receptor upregulation due to decreased estrogen binding by SHBG.
RNA polymerase III transcription initiation factor (BRF2) was elevated in cases compared to controls (log 2 ratio of 1.32). Overexpression of BRF2 has been associated with abnormal expression of E-cadherin and N-cadherin, marker proteins of the epithelial-mesenchymal transition. 40 Interestingly, proteasome subunit beta type-5 was decreased most (log 2 ratio of -1.52) in future incisional hernia patients. As part of the 20S proteasome complex, it is responsible for recognizing damaged proteins for protein quality control and proteasome inhibition and has been associated with decreased proliferation of lens epithelial cells. 41 Finally, we discovered several proteins that differ between cases and controls for which no association with wound healing or connective tissue pathophysiology has been described in the literature thus far. Gene set enrichment analysis revealed sets or families of proteins that were changed in cases compared to controls. Based on this approach, pathways of interest included extracellular matrix receptor interaction, focal adhesion, melanoma, bladder, and pathways of cancer (Table IV) .
One limitation of this study is that incisional hernias were assessed by a questionnaire and a phone interview, as physical examination by an experienced surgeon and imaging was not part of the ColoCare study design. Hence, small asymptomatic hernias may have been missed and misdiagnosis of a midline diastasis as a hernia may have occurred. Thus, our study reflects clinically apparent incisional hernias, which should be more important for clinical management. In future studies, however, we recommend performing a prospective, study-related physical examination and respective imaging at predefined time points for the assessment of incisional hernia.
Another limitation is that our study population was restricted to colorectal cancer patients only. By our stringent inclusion criteria, our case-control groups were very homogenous in their risk of developing an incisional hernia. We suggest in future directions, however, that studies should not be limited to a specific disease group to identify a robust biomarker independent of clinical or demographic parameters. A further limitation is that the medical chart reviews to collect data on clinical parameters were done retrospectively.
A limitation of the experimental array approach we used is that we were only able to evaluate biomarkers for which antibodies were included on the array. Hence, no fully comprehensive assessment of the plasma proteome was performed, and the potential of biomarkers not included on the array could not be assessed. This limited our gene set analyses in particular, as we were limited by the candidates included on the array. The array, however, covered a wide range of possible biomarker candidates yielding data on 3,290 proteins. The interpretation of the results is challenging given the study's inherent pilot discovery nature. Nonetheless, this study shows proof of principle for array-based discovery of unique, predictive biomarkers specific to incisional hernia and points to several proteins and pathways worthy of further investigation.
In this pilot study, we applied, for the first time, an antibody microarray to compare the plasma proteome of future incisional hernia patients with matched clinical controls. We showed proof of principle for the discovery of novel, plasma-based biomarkers for incisional hernia occurrence by utilizing preoperative plasma samples. Our study shows that multiple individual and groups of plasma proteins could predict the individual hernia risk prior to undergoing an operation. We were able to identify several protein biomarkers with a known association with wound healing or connective tissue pathophysiology. Promising biomarkers warrant further investigations in larger, independent sample sets to further characterize and validate their potential clinical utility. After validation, such a biomarker could be incorporated into a multifactorial risk model to guide clinical decision-making.
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